{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:26:07Z","timestamp":1775892367596,"version":"3.50.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>For almost a decade, treat-to-target (T2T) has been advocated as a management strategy for axial spondyloarthritis (axSpA), despite a lack of trial evidence. Recently, the first and only published T2T trial in axSpA did not meet its primary endpoint. The purpose of this review is to discuss whether we should continue with a T2T approach in axSpA and to describe some experiences with T2T in clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The trial showed no superiority of T2T compared with usual care; however, several secondary trial outcomes and the health economic analysis actually favoured T2T, and there are conceivable reasons for the negative trial results. Furthermore, several knowledge gaps related to an optimal T2T approach in axSpA were identified. In clinical practice, a T2T approach was applied to only a limited extent, possibly because of several challenges.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Despite one negative trial, it is too early to abandon T2T in axSpA. Not only more evidence from clinical trials but also research on the optimal target and management of all facets of axSpA, are highly needed. For successful implementation of T2T in clinical practice, it is important that barriers and facilitators to application are identified and subsequently addressed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000941","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T15:34:36Z","timestamp":1681832076000},"page":"243-248","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Go or no-go for treat-to-target in axial spondyloarthritis?"],"prefix":"10.1097","volume":"35","author":[{"given":"Casper","family":"Webers","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center"},{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin","family":"Been","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center"},{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"van Tubergen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center"},{"name":"Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","article-title":"Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial","volume":"364","author":"Grigor","year":"2004","journal-title":"Lancet"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1759720X20972610","DOI":"10.1177\/1759720X20972610","article-title":"The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study","volume":"12","author":"Redeker","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R12-20250526","first-page":"752","article-title":"Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis","volume":"28","author":"Aydin","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/annrheumdis-2018-213700","article-title":"Overdiagnosis and overtreatment in rheumatology: a little caution is in order","volume":"77","author":"Landewe","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3899\/jrheum.200934","article-title":"Residual disease burden in patients with axial spondyloarthritis and psoriatic arthritis despite low disease activity states in a multiethnic Asian Population","volume":"48","author":"Liu","year":"2021","journal-title":"J Rheumatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1136\/annrheumdis-2018-214199","article-title":"Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis","volume":"78","author":"Ferreira","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"(5 Suppl 85)","key":"R17-20250526","first-page":"S-105","article-title":"The ASAS Health Index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis","volume":"32","author":"Kiltz","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Response to: \u2019Correspondence on \u2019Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial\u201d by Cai and Peng","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R20-20250526","article-title":"Correspondence on \u2019Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial\u2019","author":"Cai","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1136\/ard.2011.150037","article-title":"A stratified model for health outcomes in ankylosing spondylitis","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R22-20250526","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8091416","article-title":"Physician adherence to treat-to-target and practice guidelines in rheumatoid arthritis","volume":"8","author":"Batko","year":"2019","journal-title":"J Clin Med"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"e000221","DOI":"10.1136\/rmdopen-2015-000221","article-title":"When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS)","volume":"2","author":"Gvozdenovic","year":"2016","journal-title":"RMD Open"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/rheumatology\/keab516","article-title":"Treat-to-target in axial spondyloarthritis: an observational study in daily practice","volume":"61","author":"Beckers","year":"2022","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:16:19Z","timestamp":1748294179000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000941","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}